Trial Lymrit 37-05

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

Lymrit 37-05

Full title

A Phase 1 Dose finding study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) in patients with relapsed/refractory, diffuse large B-cell lymphoma, not eligible for autologous stem cell transplant

Responsible organization

Nuklearmedizin

Indications

Classification	Code	Description
-		Bloodcancer (leukemia, lymphoma)

Trial design

Phase

Status

Recruitment active

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Sonstige - Therapieart: palliativ

Participants

	Function	Prename	Surname	Organization
	Responsible contact	Christian	Bogner	Nuklearmedizin